Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen

Wanggang Zhang, Fuling Zhou, Xin‐Mei Cao, Xinmei Cao, Yinxia Cheng, Yin-Xia Cheng, Aili He, Jie Liu, Xiaorong Ma, Gang Chen
Leukemia research · 2006 · vol. 30(8) , pp. 935–942 · doi:10.1016/j.leukres.2005.11.017 · PMID:16445979 · W2143348483
Non-randomised trial OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper reports the successful treatment of primary refractory anemia using a combination regimen of all-trans retinoic acid, calcitriol, and androgen.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We investigated the efficacy and safety of a combination regimen in 63 patients with primary refractory anemia (RA). The daily treatment protocol comprised all-trans retinoic acid (ATRA) (30 mg/m(2)), calcitriol (0.1 microg/m(2)), and androgen (stanozolol 3mg/m(2), or danazol 300 mg/m(2)) in three separate doses for eight consecutive weeks. Hematologic improvement was observed in 43 (68.3%) patients. The treatment administered was generally well tolerated, with no severe regimen-related toxicity. The overall survival rates at 3 and 5 years were 68.72% and 53.18%, respectively. These results indicate that this combination regimen is an effective and well-tolerated treatment for patients with RA.

My notes (saved in your browser only)

MeSH descriptors

Androgens Anemia, Refractory Calcitriol Tretinoin Adolescent Adult Aged Androgens Androgens Anemia, Refractory Anemia, Refractory Calcitriol Calcitriol Child Child, Preschool Dose-Response Relationship, Drug Drug Administration Schedule Drug-Related Side Effects and Adverse Reactions Drug Therapy, Combination Female

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (71)

Source provenance

openalex
last seen: 2026-05-11T06:41:50.100108+00:00
pubmed
last seen: 2026-10-08T21:03:37.664955+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0 · commercial use OK